After demonstrating that macropinocytosis protects sorafenib-treated HCC cells from ferroptosis, we investigated whether blocking macropinocytosis with amiloride, a clinically feasible NHE inhibitor, potentiates the antitumor effect of sorafenib [31]. The gene discussed is SLC9C1; the disease is hepatocellular carcinoma.